Recombinant Human CD90 protein (rFc Tag) (HPLC verified)

Species

Human

Purity

>90 %, SDS-PAGE
>90 %, SEC-HPLC

Tag

rFc Tag

Activity

not tested

Cat no : Eg1731

---

Validation Data Gallery

• 

  Purity of Recombinant Human CD90 was determined by SDS-PAGE. The protein was resolved in an SDS-PAGE in reducing (R) and non-reducing (NR) conditions and stained using Coomassie blue.

• 

  The purity of Human CD90 was greater than 90% as determined by SEC-HPLC.

---

Product Information

• Purity: >90 %, SDS-PAGE; >90 %, SEC-HPLC
• Endotoxin: <0.1 EU/μg protein, LAL method
• Activity:

  Not tested

• Expression: HEK293-derived Human CD90 protein Gln20-Cys130 (Accession# P04216) with a rabbit IgG Fc tag at the C-terminus.
• GeneID: 7070
• Accession: P04216
• PredictedSize: 38.8 kDa
• SDS-PAGE: 42-55 kDa, reducing (R) conditions
• Formulation: Lyophilized from 0.22 μm filtered solution in PBS, pH 7.4. Normally 5% trehalose and 5% mannitol are added as protectants before lyophilization.
• Reconstitution: Briefly centrifuge the tube before opening. Reconstitute at 0.1-0.5 mg/mL in sterile water.
• Storage Conditions:
  It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
  • Until expiry date, -20℃ to -80℃ as lyophilized proteins.
  • 3 months, -20℃ to -80℃ under sterile conditions after reconstitution.
• Shipping: The product is shipped at ambient temperature. Upon receipt, store it immediately at the recommended temperature.

Background

CD90, also known as THY1, is a 25-35 kDa glycosylphosphatidylinositol (GPI)-anchored glycoprotein that is expressed on 1-4% of human fetal liver cells, cord blood cells, and bone marrow cells. CD90 is one of the essential surface molecules expressed on human MSC from bone marrow and other sources. Activation of Thy-1 has been reported to promote T cell activation. It also affects numerous nonimmunologic biological processes, including cellular adhesion, neurite outgrowth, tumor growth, migration, and cell death.

References:

1. Wiesmann A, et al. (2006). Head Face Med. Mar 31;2:8. 
2. Moraes D.A,.et al. (2016). Stem Cell Res Ther. Jul 28;7(1):97. 
3. He J, et al. (2012). Mol Cell Proteomics. Jun;11(6):M111.010744.